Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
Supplementation with vitamin D3 in premenopausal women does not have a significant effect on breast density percentage, nor does it reduce breast cancer risk.
Daily Oncology News
Older Age Patients with HNSCC Benefit from Afatinib vs Methotrexate
Patients age 65 years or older with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) did not have worse clinical outcomes.
Neratinib Not Superior to Trastuzumab for ERBB2+ Metastatic Breast Cancer
Neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel with respect to progression-free survival as first-line treatment.
Structured Exercise Programs Effectively Lead to Increased Physical Activity Among Trial Participants
A structured exercise program more effectively increased physical activity among patients participating in a clinical trial.
Optimal Tumor Reduction, Platinum Sensitivity Characterize Long-term Ovarian Cancer Survival
Women who are long-term survivors of high-grade serous carcinoma (HGSC) usually have platinum-sensitive disease.
Targeted Therapies Suppress T-cell Response But Superagonist Can Overcome the Suppression
Dozens of targeted therapies, which are preferred as treatment over chemotherapy and surgery, suppress the activity of T cells that could help to fight tumors.
Reasons for Mind-body Therapy Use Among Cancer Survivors Vary by Stage
Cancer survivors use mind-body therapies (MBTs) to manage their cancer-related symptoms, but this use may differ for each cancer survivorship stage.
Efficacy of First-line Ponatinib in CP-CML Remains Unclear
Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).
Afatinib Improves Outcomes vs Gefitinib in Treatment-naïve EGFR-mutant NSCLC
Afatinib significantly improved outcomesin treatment-naïve patients with EGFR-mutant non-small cell lung cancer (NSCLC).
Substantial Increase in Use of Neoadjuvant Chemoradiotherapy for Rectal Cancer
Use of neoadjuvant chemoradiotherapy (NACRT) before surgery among patients with rectal cancer has substantially increased over the past decade.
Want to read more?
Please login or register first to view this content.
Next post in Daily Oncology News
